Skip to main content

Table 6 Main and secondary outcomes for website groups at twelve week follow up

From: Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website

Variable

Website

Website + support

No website group

Significance

IBS-SSS total mean (n = 123)

207.9 (187.6 – 228.1)

193.4 (173.0- 213.8)

218.2 (197.4-238.9)

p = 0.243

IBS-QOL score (n = 123)

71.6 (67.2 - 76.1)

69.5 (65.0 - 74.0)

64.3 (59.8 – 68.9)

p = 0.068

HADS score for anxiety (n = 114)

8.8 (8.0- 9.7)

9.2 (8.3 -10.0)

8.0 (7.1 -8.8)

p = 0.123

HADS score for depression (n = 114) (%)

   

p = 0.981

Normal (0–7)

32 (84.2)

31 (79.5)

30 (81.1)

 

Mild (8–10)

6 (15.8)

4 (10.3)

4 (10.8)

 

Moderate or Severe (11–21)

0 (0)

4 (10.3)

3 (8.1)

 

Enablement score (n = 113) (%)

   

p = 0.000**

0

7 (18.4)

4 (10.5)

21 (56.8)

 

1-2

7 (18.4)

5 (13.2)

4 (10.8)

 

3-5

13 (34.2)

15 (39.5)

7 (18.9)

 

6-12

11 (28.9)

14 (36.8)

5 (13.5)

 

SGA (%)

    

Responders

16 (45.7)

24 (63.2)

12 (32.4)

p = 0.035*

Non responders

19 (54.3)

14 (36.8)

25 (67.6)

 
  1. Analysis of the 12 week follow-up scores.
  2. ANCOVA for IBS SSS, IBS-QOL and HADs Anxiety, Mean (95% CI). Ordinal Regression for HADs Depression, Enablement and SGA (n (%).